JAK2 and plasma cell myeloma: An earlier study reported that EP can potentially induce the antitumor effects in multiple myeloma U266 cells; simultaneously, it can act as an antiangiogenic agent through the targeting of the JAK2/STAT3 signaling pathway [20].